Wednesday 14th July. Time: 7.30-9pm
This webinar will be a primary care focused presentation covering cancer genetics, direct to consumer testing, pharmacogenetics, rare complex genetic disease and a look to the future.
Dr Will Evans is a GP in Leeds, a honorary (clinical) assistant professor at the University of Nottingham, the clinical lead at Mendelian, a health technology company using data driven approaches to identify rare disease patients and the chairman of a rare disease patient advocacy group, Niemann-Pick UK. His interests include genomics in primary care, rare diseases and the use of routinely collected information in the electronic health record to help guide the diagnosis and management of rare disease patients.
1) To understand the impact of genetics on cancer diagnoses.
2) To gain knowledge of resources to support your decision making about which cancer patients and family members should be referred for further investigation.
3) To recognise the opportunities and limitations of direct-to-consumer testing and give you an approach to address patients presenting to primary care with such a report.
4) To gain insights on which drugs, frequently prescribed in primary care, have pharmacogenetic implications and how this may evolve in the future.
5) When to think which of your patients may have an undiagnosed rare genetic disease.
AiT rate - £15
RCGP Member rate - £20
Non-Member rate - £30